



March 17, 2016

Dear Manufacturers,

I am writing on behalf of McLaren Oakland (DSH230207) to inform manufacturers that MO recently underwent an audit by the Health Resources and Services Administration (HRSA) of MO's compliance with 340B Drug Pricing Program (340B Program) requirements.

As a background, MO qualified for the 340B Program as a disproportionate share hospital (DSH) located in an impoverished area, 50 North Perry St, Pontiac, MI 48342 and has participated in the 340B program since January 2005.

Through the audit process, MO was found to have non-compliance within their 340B program and responsible for repayment as a result of the following finding:

Finding: MO dispensed 340B drugs to ineligible individuals, as prohibited by section 340B (a)(5)(B) of the PHSA.

Finding 3: MO listed incorrect or incomplete billing information on the 340B Medicaid Exclusion File.

MO has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from MO and believe repayment may be owed for the violation, described in this letter, or if you have any question or comments regarding the violation described in this letter please contact Fred Korte, Chief Financial Officer, (248)338-5686, 50 North Perry St, Pontiac, MI 48342 or via e-mail fred.korte@mcclaren.org .

Sincerely,

Fred Korte, Chief Financial Officer
McLaren Oakland